Publikationen in Zusammenarbeit mit Forschern von Universidad Católica San Antonio (34)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  3. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis

  4. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial

    Chest, Vol. 165, Núm. 3, pp. 673-681

  5. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  4. Clinical Significance and Outcome in Patients with Asymptomatic Versus Symptomatic Subsegmental Pulmonary Embolism

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  5. Identification of Low-risk Patients With Acute Symptomatic Pulmonary Embolism

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 575-580

  6. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  7. The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism

    American Heart Journal, Vol. 257, pp. 62-68

  8. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  9. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  2. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 725-734

  3. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

  4. The hazard of combining anticoagulants with antiplatelets in patients with venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  5. Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation

    British journal of haematology, Vol. 197, Núm. 4, pp. 489-496

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989